AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
The original release is unavailable here.
Earlier from Abbvie
- AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
- AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
- U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease
- EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma